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Abstract
Introduction. Aldosterone promotes renal fibrosis
via the mineralocorticoid receptor (MR), thus
contributing to hypertension-induced
nephropathy. We investigated whether MR gene
expression influences renal fibrosis and MR
antagonist response in a two-kidney, one-clip
hypertensive rat model.
Materials and methods. Brown Norway (BN),
Lewis, and ACI rats were randomised to
spironolactone 20 mg/kg/day or water by
gavage, starting four weeks after left renal artery
clipping. Blood pressure was measured bi-weekly
by tail cuff. After eight weeks of treatment, right
kidneys were removed and examined for fibrosis
and gene expression. Rats of each strain
undergoing no intervention served as controls.
Results. Blood pressure increased similarly
among strains after clipping and was unaffected
by spironolactone. Hypertension caused the
greatest renal fibrosis in BN rats (p < 0.001 by
ANOVA compared to other strains). Real-time
PCR analysis showed greater renal collagen type
I and MR gene expression in untreated,
hypertensive BN rats (both p < 0.05 compared to
other strains). Spironolactone attenuated fibrosis,
with similar fibrosis among strains of
spironolactone-treated rats.
Conclusion. Hypertension-induced renal fibrosis
was greatest in rats with the highest MR gene
expression. Spironolactone abolished inter-strain
differences in fibrosis. Our data suggest that MR
genotype may influence aldosterone-induced
renal damage, and consequently, renal response
to aldosterone antagonism.
Introduction
Aldosterone contributes to hypertension-induced
renal damage by promoting renal inflammation,
glomerular injury, and abnormal accumulation
of fibrillar collagens.1-3 The renal effects of
aldosterone are believed to be mediated via the
mineralocorticoid receptor (MR; NR3C2), a member
of the nuclear receptor superfamily.4 MR antago-
nism with spironolactone has been shown to pro-
vide renal protective effects through mechanisms
independent of blood pressure reduction.5-7
There is evidence of inter-patient variability in
susceptibility to hypertension-induced renal dam-
age.8,9 In addition, we have previously described
inter-patient differences in response to MR antag-
onists.10 Polymorphisms in genes encoding for
proteins involved in the pathogenesis of hyper-
tension-induced organ damage are believed to
contribute to the inter-patient variability in target
organ complications.11 Similarly, inter-patient dif-
ferences in drug response may be largely attrib-
uted to genetic polymorphisms for proteins
involved in drug disposition or pharmacodynam-
ics.12 Given that the MR is expressed in renal tis-
sue and that MR antagonists attenuate aldosterone-
mediated injury, the MR gene is a potential can-
didate for influencing response to aldosterone
and MR antagonists.2,4 We hypothesised that
aldosterone-mediated effects on the kidney and
spironolactone response vary by MR genotype.
We exposed three strains of normotensive inbred
rats to renovascular hypertension using a two-
kidney, one-clip model (Goldblatt model). Using
this model, we sought to determine whether MR
gene expression is associated with renal fibrosis
and attenuation of fibrosis with spironolactone.
Materials and methods
Animals
Experiments were conducted in male Brown
Norway (BN/RijHsd), Lewis (Lew/SsNHsd), and
ACI (ACI/SegHsd) rats. Brown Norway (BN) and
Lewis rats were previously shown to have differ-
ent MR genotypes, while MR genotype is similar
in Lewis and ACI strains.13 Differential findings
between the BN and Lewis strains would impli-
cate the MR gene as a potential contributing
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factor, while differences between the Lewis and
ACI strains would implicate the involvement of
other genes.
Thirty-two rats of each strain, 10 weeks of age,
were obtained from Harlan Sprague–Dawley, Inc.
(Indianapolis, IN, USA) and randomised into three
groups: (1) clip-untreated (14 rats of each strain);
(2) clip-spironolactone (14 rats of each strain); and
(3) control (four rats of each strain). Control ani-
mals were primarily included for blood pressure
comparisons to ascertain the effectiveness of renal
artery clipping. Animals were housed two per cage
in a room with a 12-hour light/dark cycle and free
access to standard rat chow (0.3% sodium) and
allowed two weeks to adjust after arrival before
undergoing surgery. All animal protocols were
approved by the Institutional Animal Care
Committee at the University of Illinois at Chicago
and conducted according to the Guiding Principles
in the Care and Use of Animals of the American
Physiological Society.
Two-kidney, one-clip hypertension
At 12 weeks of age, clip-untreated and clip-
spironolactone rats were weighed and anaes-
thetised with ketamine 90 mg/kg plus xylazine
3 mg/kg by intraperitoneal injection. Under asep-
tic conditions, the abdomen was shaved, and a
left lateral abdominal incision exposed the kidney.
The left renal artery was freed from the retroperi-
toneal tissue and dissected from the renal vein. A
clip (0.203, 0.214, or 0.229 mm in diameter) con-
structed from silver wire (MWS Wire Industries,
Westlake Village, CA, USA) was placed around
the left renal artery. The clip size that constricted
renal blood flow without completely occluding
the renal artery, as visualised by microscopy, was
used. The kidney and artery were placed back in
situ, and the incision was closed with nylon
sutures. Post-operatively, rats were placed on a
heating blanket in a clean cage with standard
chow and tap water ad libitum and treated with
buprenorphine 0.1 mg/kg by subcutaneous injec-
tion every six hours for two doses. Once sutures
were removed, animals were re-housed with their
original cage mates.
Blood pressure analysis
Systolic blood pressure was measured before and
bi-weekly after clipping by a non-invasive tail cuff
system (Model 29-SSP, IITC Inc., Life Science,
Woodland Hills, CA, USA). Control rats also under-
went bi-weekly blood pressure measurement,
beginning at 12 weeks of age. Animals were
warmed to 30ºC, and the cuff was placed at the
base of the tail prior to measurement. Blood pres-
sure measurements were repeated approximately
every two minutes until two readings within
5 mmHg were obtained. All blood pressure meas-
urements were done between 1:00 p.m. and 4:00
p.m. Renal artery clipping was deemed successful
if average systolic blood pressure from weeks two
through 12 after clipping was ≥ 160 mmHg.
Spironolactone treatment
Treatment with 20 mg/kg/day of spironolactone
(Sigma-Aldrich Corp., St. Louis, MO, USA) by gav-
age was started four weeks after surgery and con-
tinued for eight weeks. Clip-untreated rats were
gavaged daily with water, and control animals
received no treatment. A spironolactone 5 mg/ml
suspension, prepared by combining spironolac-
tone, 1% methylcellulose, 0.2% Tween-80, and fil-
tered water, was stored at 4ºC and shaken well
before each use. Rats were weighed weekly, and
the spironolactone dose was adjusted accordingly.
Urine and tissue collection
At 24 weeks of age, rats were housed individually
in metabolic cages with tap water ad libitum and
without rat chow for 24-hour urine collection.
Then, rats were anaesthetised with intraperitoneal
ketamine 90 mg/kg plus xylazine 3 mg/kg and
weighed. The right (unclipped) kidney was rap-
idly excised, rinsed, weighed, and frozen in
liquid nitrogen. Tissue was stored at −70ºC until
collagen and gene expression studies.
Hydroxyproline assay
Collagen content of the right kidney was deter-
mined by hydroxyproline assay in control rats
and five random clip-untreated and clip-spirono-
lactone rats of each strain, as previously described.3
Briefly, approximately 40 mg of tissue was excised
from the mid region of the right kidney and freeze
dried, weighed, cut into small pieces, and washed
five times in a solution of 0.1 mol/L NaCl and
5 mmol/L NaHCO3. Each sample was then hydrol-
ysed in 700 µl of 6N HCl for 16 hours at 110°C, fil-
tered, vacuum dried overnight, and dissolved in
deionised water. Hydroxyproline content was
determined by the method of Stegemann and
Stalder14 using a colourimetric assay and standard
curve of 0 µg to 5 µg hydroxyproline. The data
were expressed as µg collagen/mg dry weight,
assuming that collagen contains an average of
13.5% hydroxyproline.15
Aldosterone assay
The total amount of urine produced was recorded,
and a well mixed aliquot was preserved with
boric acid 10 mg/ml and stored at 4ºC for up to
one month until analysis. Urinary aldosterone con-
centrations were determined in duplicate by radio -
immunoassay with iodine-125-labelled aldosterone
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(Diagnostic Systems Laboratories, Webster, TX,
USA) according to the manufacturer’s instructions.
RNA isolation and cDNA synthesis
RNA was isolated from tissue taken from the mid
section of the right kidney of all control, clip-
untreated, and clip-spironolactone rats of each
strain using TRIzolReagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s proto-
col. Total RNA (1 µg) was DNase-treated using
proprietary reaction buffer and enzyme
(Fermentas, Hanover, MD, USA). RNA, DNase,
and buffer were incubated at 37ºC for 30 minutes.
DNase was then heat inactivated at 75ºC for 5
minutes. This reaction product was reverse tran-
scribed into cDNA using Oligo(dT) Primer and M-
MLV Reverse Transcriptase (Invitrogen) according
to the manufacturer’s protocol.
Real-time PCR
cDNA generated by the reverse transcriptase
reaction was used as a template in the quantita-
tive real-time PCR assay (qPCR). qPCR primers
(table 1) for MR, collagen α1 type I, and the house-
keeper gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were designed using Primer
Quest software (Integrated DNA Technologies,
Correlville, IA, USA). The qPCR assay was carried
out in triplicate using an ABI 7900HT detection
system and SYBR Green PCR Mix for ABI PRISM
(Applied Biosystems, Foster City, CA, USA). In
short, 12.5 µl master mix containing Taq DNA
polymerase, reaction buffer, deoxynucleoside
triphosphate mix, and SYBR Green I dye was
combined with 2.5 µM concentration of appro-
priate primers and 2 µl of cDNA. The thermocy-
cling protocol was: 50°C for two minutes,
denaturation at 95°C for 10 minutes, and 40 cycles
of 95°C for 15 seconds and 60°C for 60 seconds.
The temperature transition rate was 20°C/second.
Fluorescence was measured at the end of each
extension step. After amplification, a melting curve
was acquired by heating the product at 20°C/
second to 95°C, cooling it at 20°C/second to 60°C,
keeping it at 60°C for 20 seconds, and then slowly
heating it at 0.1°C/second to 95°C. Fluorescence was
measured through the slow heating phase. The
efficiency of each primer set was calculated with
serial dilutions of cDNA in a qPCR assay, and then
the primer efficiency was used to calculate the
expression ratio of MR and collagen type I relative
to GAPDH, as previously described by Pfaffl.16 The
mRNA quantity of 1 µg was normalised to the
mRNA quantity of the endogeneous control gene
GAPDH from the same sample. Specificity of
qPCR primers was confirmed using melting curves
and gel electrophoresis. As a negative control, total
RNA samples were DNase-treated and then put
through reverse transcription in which all reagents
except for reverse transcriptase were present. The
resulting samples did not PCR, confirming that
there was no genomic DNA contamination in the
samples tested.
Data analysis
Data were compared between groups within
each strain (control versus clip-untreated or clip-
untreated versus clip-spironolactone) by the
Student’s unpaired t-test. Data were compared
among the three strains by one-way analysis of
variance (ANOVA), with subsequent pairwise
comparisons by the Student’s unpaired t-test.
Power calculations were based on determining a
significant difference between strains in attenua-
tion of renal collagen content (collagen content
in untreated rats minus collagen content in
treated rats) with spironolactone. Including at
least five untreated and five treated rats of each
strain was estimated to provide 80% power to
detect a 30 mcg/mg difference in renal collagen
regression among strains with an α of 0.05 (two-
tailed test), assuming a pooled standard deviation
of 10 mcg/mg.
Results
Systolic blood pressure
Renal artery clipping successfully increased sys-
tolic blood pressure without causing renal infarc-
tion in 20 BN rats (nine clip-untreated and 11
clip-spironolactone rats), 21 Lewis rats (10 clip-
untreated and 11 clip-spironolactone rats), and 21
ACI rats (nine clip-untreated and 12 clip-spirono-
lactone rats). Blood pressure increased similarly
Table 1
Real-time PCR primer sequences.
Gene Primer sequence Product size (bp) Accession no.
MR 5’-GCCCGGCAAATCTCAACAACTCAA-3’
5’-TTAGGGAAAGGAACGTCGTGAGCA-3’ 235 M36074
Collagen type I 5’-AGCAAAGGCAATGCTGAATCGTCC-3’
5’-TGCCAGATGGTTAGGCTCCTTCA-3’ 125 Z78279
GAPDH 5’-TGACTCTACCCACGGCAAGTTCAA-3’
5’-ACGACATACTCAGCACCAGCATCA-3’ 141 X02231
Key: MR=mineralocorticoid receptor; GAPDH=glyceraldehyde-3-phosphate dehydrogenase.
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among strains, as shown in figure 1. Among clip-
untreated rats, the mean±SD systolic blood pres-
sure over the 12-week period following surgery
was 182±10 mmHg in BN rats and 182±12 mmHg
in both Lewis and ACI rats. Spironolactone had
no effect on blood pressure in any of the three
strains.
Aldosterone excretion
Aldosterone excretion was greater in clip-untreated
BN and ACI, but not Lewis rats, compared to respec-
tive controls, as shown in table 2. Aldosterone excre-
tion was greater in ACI (p < 0.05) and tended to be
greater in BN (p=0.05) rats compared to Lewis rats
after clipping. Spironolactone had no effect on
aldosterone excretion in any of the three strains.
Renal measurements
The weight ratio of the right to left kidney was
significantly higher in clip-untreated animals
compared to controls of each strain and was not
affected by spironolactone (table 2). The weight
ratio did not differ among the three strains.
However, renal collagen content differed signifi-
cantly among strains of clip-untreated rats, as
shown in figure 2 (p < 0.01 by ANOVA). With
clipping, renal collagen deposition significantly
increased in BN and ACI, but not Lewis rats,
Figure 1
Systolic blood pressures measured bi-weekly using a non-invasive tail cuff system in control, clip-untreated, and clip-spironolac-
tone rats of the Brown Norway, Lewis, and ACI strains. Clip rats underwent a two-kidney, one-clip procedure at 12 weeks of age.
Clip-spironolactone rats received spironolactone 20 mg/kg/day by gavage from weeks 16 to 24. Values represent mean±SEM.
*p < 0.01, †p < 0.05 for clip-untreated and clip-spironolactone groups compared to control.
Table 2
Aldosterone excretion, body weight, and right kidney weight at 24 weeks of age.
Aldosterone Body weight Right kidney/left
Strain (ng/day) (gm) kidney weight
Brown Norway
Control (n=4) 7.9±3.5 281±11 1.05±0.03
Clip-untreated (n=9) 20.5±9.3* 298±27 1.20±0.13*
Clip-spironolactone (n=11) 17.0±7.3* 304±22* 1.37±0.35*
Lewis
Control (n=4) 8.9±2.4 351±29 1.02±0.02
Clip-untreated (n=10) 11.0±8.3 355±42 1.48±0.56*
Clip-spironolactone (n=11) 10.1±8.7 313±40 1.43±0.31*
ACI
Control (n=4) 4.7±0.9 249±6 1.06±0.06
Clip-untreated (n=9) 24.2±15.9* 232±14* 1.25±0.18*
Clip-spironolactone (n=12) 22.1±9.8* 218±20* 1.23±0.17*
Key: Mean±SD; *p < 0.05 versus control rats of the same strain.
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compared to controls. Collagen was greater in
clip-untreated BN rats compared to clip-untreated
ACI rats (p < 0.05) and nearly two-fold greater
than in clip-untreated Lewis rats (p < 0.01).
Spironolactone significantly reduced renal fibro-
sis in BN and ACI strains, although the reduction
in ACI rats was of borderline significance. In con-
trast, spironolactone had no effect in Lewis rats.
In the BN strain, renal collagen was similar in
clip-spironolactone and control rats. However, in
the ACI strain, renal collagen remained two-fold
higher in clip-spironolactone rats compared to
controls.
Gene expression
Real-time PCR efficiencies were as follows: 0.59
for GAPDH, 0.98 for collagen type I, and 0.70 for
MR and in the investigative range from 0.20 to
50 ng of cDNA. Collagen type I gene expression
increased significantly in the right renal tissue
after clipping in BN and ACI, but not Lewis rats
(figure 3). Clip-untreated BN rats had the greatest
collagen gene expression (p < 0.01 compared to
the other two strains). Spironolactone treatment
tended to attenuate the increase in collagen type
I gene expression in BN and ACI rats, although
the difference between clip-untreated versus
treated rats did not reach statistical significance.
Renal MR gene expression differed among strains
of control rats (p < 0.01), as shown in figure 4,
with the greatest MR gene expression in BN rats.
MR gene expression increased significantly with
clipping in BN rats, with greater MR gene expression
in this strain compared to both Lewis (p < 0.01) and
ACI (p < 0.01) rats. Spironolactone-treated BN rats
had lower MR gene expression relative to GAPDH
compared to clip-untreated rats (0.026±0.002
versus 0.056±0.001, p=0.04). MR gene expression
did not differ between treated and untreated rats
of the other two strains.
Discussion
The two-kidney, one-clip model is a renovascular
hypertension model in which reduced renal per-
fusion leads to activation of the renin-angiotensin
system, increased aldosterone secretion from the
adrenal gland, and sustained elevations in blood
pressure. Using this model, we found significant
hypertension-induced increases in renal collagen
deposition and gene expression in BN and ACI,
Figure 2
Renal collagen content as measured by hydroxyproline assay in four control, five clip-untreated, and five clip-spironolactone rats
of the ACI, Brown Norway, and Lewis strains at 24 weeks. Clip-spironolactone rats received spironolactone 20 mg/kg/day by gav-
age from weeks 16 to 24. Values represent mean±SEM.
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Figure 3
Renal collagen type I gene expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in control, clip-untreated,
and clip-spironolactone rats of each strain. Values represent mean±SEM.
Figure 4
Renal mineralocorticoid receptor gene expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in control, clip-
untreated, and clip-spironolactone rats of each strain. Values represent mean±SEM. *p < 0.01 compared to control rats of the
Lewis and ACI strains; †p < 0.01 compared to clip-untreated rats of the Lewis and ACI strains.
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but not Lewis rats. BN rats had the greatest fibrosis
and collagen gene expression. Aldosterone
antagonism attenuated renal fibrosis in the BN
strain, and to a lesser extent in the ACI strain,
without affecting blood pressure. Overall, our
data suggest that BN rats are particularly prone to
hypertension-induced renal damage. This is con-
sistent with findings from other investigators.17,18
Our data also suggest that BN rats may derive
particular benefit, in terms of renal protection,
from aldosterone antagonism. To our knowledge,
this has not been previously reported.
Our findings of differential hypertension-induced
renal damage and spironolactone response among
inbred rat strains with similar blood pressures and
maintained under similar conditions suggest that
genetic factors contributed to observed inter-strain
differences. There are a number of potential can-
didate genes underlying the differential renal
effects. We chose to focus on the MR gene, given
that it is the target site for aldosterone and aldos-
terone antagonists. In addition, other investiga-
tors have described differing MR genotypes
between BN and Lewis rats.13 Greater MR gene
expression in renal tissue of BN rats compared
to the other strains in our study implicates the
MR gene as a contributor to the inter-strain dif-
ferences in renal fibrosis and spironolactone
response.
Increased MR gene expression after renal artery
clipping in the BN strain in our study is consistent
with previous observations. Specifically, aldos-
terone has been shown to significantly increase
MR mRNA concentration in vitro.19 Similarly,
increased MR gene expression has been observed
in both post-myocardial infarction and heart fail-
ure rat models.20,21 These findings are consistent
with the MR functioning as a ligand-inducible
transcription factor, a characteristic of nuclear
receptors.22 In light of these data, perhaps what is
most striking about our findings is the absence of
increased MR gene expression in the presence of
elevated aldosterone in the ACI strain, thereby
suggesting that there may be inter-strain variabil-
ity in the degree of aldosterone-mediated upreg-
ulation of MR gene expression. In particular, our
data suggest that there may be inter-strain differ-
ences in the ligand-binding domain of the MR.
Spironolactone suppressed the rise in MR gene
expression in BN rats. This finding is also in line
with previous reports, in that attenuation of MR
gene expression levels with MR antagonist ther-
apy has been demonstrated in both post-infarct
and heart failure rat models.20,21 While the exact
mechanism by which spironolactone exerts its
effects is unclear, data from our study and others
suggest that spironolactone may inhibit hyperten-
sion-induced renal fibrosis by modulating MR
gene expression levels.20
We observed some attenuation of renal fibrosis
among spironolactone-treated hypertensive ACI
rats, even though MR gene expression was not
increased in this strain. This is possibly due to
spironolactone’s suppression of aldosterone-
induced fibrosis mediated through non-genomic
pathways. In support of this possibility, aldos-
terone has been shown to induce rapid (non-
genomic) cellular responses resulting in collagen
deposition.23 These rapid effects were inhibited
with MR blockade.23 Another possibility is that
spironolactone, which lacks specificity for the
MR, inhibits renal injury mediated through
other nuclear hormone receptors. In particular,
spironolactone has potent anti-androgen effects.24
There is evidence that testosterone stimulates
fibrosis in the kidney.25,26 The pro-fibrotic effects
of aldosterone could potentially be attenuated by
androgen receptor blockade with spironolactone.
Of note, neither aldosterone concentration nor
renal fibrosis increased significantly in Lewis rats
with renal artery clipping. In contrast, hyperten-
sion resulted in increases in both aldosterone
excretion and renal fibrosis in the BN and ACI
strains. One potential explanation for the lack of
hypertension-induced renal fibrosis in the Lewis
strain is that this strain had a diminished aldos-
terone response to renin-angiotensin system stim-
ulation. However, this explanation is speculative
since renin concentrations were not measured in
the current study.
There are some additional limitations to our study
that should be addressed. First, untreated rats
were gavaged with water, rather than the vehicle
used in the spironolactone preparation. As such,
we are not able to account for any potential phar-
macologic effects due to the vehicle versus
spironolactone. In addition, we did not measure
serum or urinary electrolytes in the current study.
Thus, whether the effects of aldosterone or MR
blockade on electrolyte homeostasis varied by rat
strain or gene expression is unknown.
Our findings of greater MR gene expression and
renal fibrosis in BN versus ACI rats, despite simi-
lar aldosterone concentrations between strains,
suggest that the MR gene is involved in deter-
mining susceptibility to renal injury from hyper-
tension. If associations between the MR gene and
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predisposition to renal disease are identified in
humans, then knowledge of MR genotype could
have important clinical implications. Specifically,
information about MR genotype may be useful in
identifying patients at high risk for hypertension-
induced renal damage, in whom, more aggressive
blood pressure lowering, and potentially therapy
with an MR antagonist, may be instituted.
Conclusion
In summary, renovascular hypertension produced
differential renal fibrosis in three strains of inbred
rats. The strain with the greatest MR gene expres-
sion had the greatest renal collagen content and
collagen gene expression. Treatment with spirono-
lactone abolished the excessive fibrosis in the rat
strain with elevated MR expression. On the other
hand, spironolactone only partially attenuated
fibrosis in the rat strain without an aldosterone-
mediated increase in MR gene expression. These
data suggest that MR genotype may influence the
degree of MR gene expression and renal damage in
renin-dependent hypertension, and consequently,
the renoprotective effect of MR antagonism.
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